HIV Reservoirs As Obstacles and Opportunities for an HIV Cure

Overview

Journal Nat Immunol

Date 2015 May 21

PMID 25990814

Citations 137

Authors

Tae-Wook Chun

Susan Moir

Anthony S Fauci

Affiliations

Soon will be listed here.

Abstract

The persistence of HIV reservoirs remains a formidable obstacle to achieving sustained virologic remission in HIV-infected individuals after antiretroviral therapy (ART) is discontinued, even if plasma viremia has been successfully suppressed for prolonged periods of time. Numerous approaches aimed at eradicating the virus, as well as maintaining its prolonged suppression in the absence of ART, have had little success. A better understanding of the pathophysiologic nature of HIV reservoirs and the impact of various interventions on their persistence is essential for the development of successful therapeutic strategies against HIV or the long-term control of infection. Here, we discuss the persistent HIV reservoir as a barrier to cure as well as the current therapeutic strategies aimed at eliminating or controlling the virus in the absence of ART.

Citing Articles

Immune Alterations and Viral Reservoir Atlas in SIV-Infected Chinese Rhesus Macaques.

Clain J, Picard M, Rabezanahary H, Andre S, Boutrais S, Goma Matsetse E Infect Dis Rep. 2025; 17(1).

PMID: 39997464 PMC: 11855486. DOI: 10.3390/idr17010012.

The Proviral Reservoirs of Human Immunodeficiency Virus (HIV) Infection.

Murzin A, Elfimov K, Gashnikova N Pathogens. 2025; 14(1).

PMID: 39860976 PMC: 11768375. DOI: 10.3390/pathogens14010015.

CCR5-ligand decorated rilpivirine lipid-based nanoparticles for sustained antiretroviral responses.

Patel M, Panja S, Zaman L, Yeapuri P, Bhattarai S, Gorantla S Nat Commun. 2025; 16(1):513.

PMID: 39779664 PMC: 11711180. DOI: 10.1038/s41467-024-55544-9.

Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice.

Jain J, Pham T, Begum S, Romero-Medina M, Bellini N, Li Y iScience. 2025; 27(12):111470.

PMID: 39758987 PMC: 11699618. DOI: 10.1016/j.isci.2024.111470.

Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.

Rai M, Blazkova J, Kardava L, Justement J, Shi V, Manning M Nat Med. 2025; 31(2):427-432.

PMID: 39753965 DOI: 10.1038/s41591-024-03357-0.

References

Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio F, Yassine-Diab B . HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009; 15(8):893-900. PMC: 2859814. DOI: 10.1038/nm.1972. View

Corey L, Nabel G, Dieffenbach C, Gilbert P, Haynes B, Johnston M . HIV-1 vaccines and adaptive trial designs. Sci Transl Med. 2011; 3(79):79ps13. PMC: 3616511. DOI: 10.1126/scitranslmed.3001863. View

Yukl S, Boritz E, Busch M, Bentsen C, Chun T, Douek D . Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 2013; 9(5):e1003347. PMC: 3649997. DOI: 10.1371/journal.ppat.1003347. View

Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

Margolis D . Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS. 2011; 6(1):25-9. PMC: 3079555. DOI: 10.1097/COH.0b013e328341242d. View

Burton D, Ahmed R, Barouch D, Butera S, Crotty S, Godzik A . A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 2012; 12(4):396-407. PMC: 3513329. DOI: 10.1016/j.chom.2012.09.008. View

Siliciano J, Kajdas J, Finzi D, Quinn T, Chadwick K, Margolick J . Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003; 9(6):727-8. DOI: 10.1038/nm880. View

Chun T, Murray D, Justement J, Blazkova J, Hallahan C, Fankuchen O . Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc Natl Acad Sci U S A. 2014; 111(36):13151-6. PMC: 4246957. DOI: 10.1073/pnas.1414148111. View

Barouch D, Whitney J, Moldt B, Klein F, Oliveira T, Liu J . Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013; 503(7475):224-8. PMC: 4017780. DOI: 10.1038/nature12744. View

10.

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

11.

Deng K, Pertea M, Rongvaux A, Wang L, Durand C, Ghiaur G . Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015; 517(7534):381-5. PMC: 4406054. DOI: 10.1038/nature14053. View

12.

Rasmussen T, Tolstrup M, Brinkmann C, Olesen R, Erikstrup C, Solomon A . Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2015; 1(1):e13-21. DOI: 10.1016/S2352-3018(14)70014-1. View

13.

Chun T, Justement J, Murray D, Kim C, Blazkova J, Hallahan C . Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J Infect Dis. 2013; 208(9):1443-7. PMC: 3789563. DOI: 10.1093/infdis/jit306. View

14.

Elliott J, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron M . Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 2014; 10(10):e1004473. PMC: 4231123. DOI: 10.1371/journal.ppat.1004473. View

15.

Fletcher C, Staskus K, Wietgrefe S, Rothenberger M, Reilly C, Chipman J . Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A. 2014; 111(6):2307-12. PMC: 3926074. DOI: 10.1073/pnas.1318249111. View

16.

Kordelas L, Verheyen J, Beelen D, Horn P, Heinold A, Kaiser R . Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med. 2014; 371(9):880-2. DOI: 10.1056/NEJMc1405805. View

17.

Chun T, Engel D, Berrey M, Shea T, Corey L, Fauci A . Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998; 95(15):8869-73. PMC: 21169. DOI: 10.1073/pnas.95.15.8869. View

18.

Bullen C, Laird G, Durand C, Siliciano J, Siliciano R . New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014; 20(4):425-9. PMC: 3981911. DOI: 10.1038/nm.3489. View

19.

Moir S, Malaspina A, Fauci A . Prospects for an HIV vaccine: leading B cells down the right path. Nat Struct Mol Biol. 2011; 18(12):1317-21. DOI: 10.1038/nsmb.2194. View

20.

Walker B, Yu X . Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol. 2013; 13(7):487-98. DOI: 10.1038/nri3478. View